Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Merck & Co.
41 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Vaccine
Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating Pneumococcal Conjugate Vaccine
M&A
TriRx Pharmaceutical Services Acquires MSD Animal Health Manufacturing Site located in Segre-en Anjou Bleu, France Including Long-term Supply Agreement
PR-M09-20-NI-01
Collaboration
Merck and IRBM Announce Pioneering Collaboration to Advance Peptide Therapeutics
PR-M07-20-NI-33
COVID-19 Vaccine
IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
PR-M05-20-NI-036
M&A
Merck to Acquire Themis
PR-M05-20-NI-035
Emergency Response
Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
PR-M04-20-NI-008
Medical Professionals Across Merck, Pfizer, and Eli Lilly Volunteer Amid COVID-19 Pandemic
PR-M04-20-NI-004
3D Printing
Merck KGaA, Darmstadt, Germany and AMCM / EOS Cooperate in 3D Printing of Tablets
PR-M02-20-NI-042
M&A
Merck to Acquire ArQule, Advancing Leadership in Oncology
PR-M12-19-NI-017
Vaccine Approval
Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
PR-M11-19-NI-011
FDA Approval
U.S. FDA Approved New Antibacterial for Urinary Tract and Abdominal Infections
PAO-M08-19-NI-015
Vaccine
CDC Advisory Recommends Vaccination of Adults Ages 27-45 with GARDASIL®9 & Harmonization of Catch-up Vaccination for Males and Females Through Age 26
PR-M07-19-NI-004
Track and Trace
IBM, KPMG, Merck and Walmart to Collaborate as Part of FDA’s Program to Evaluate the Use of Blockchain to Protect Pharmaceutical Product Integrity
PR-M06-19-NI-021
M&A
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
PR-M05-19-NI-067
Restructuring
Merck Undergoes Restructuring
PAO-M05-19-NI-009
Announcement
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
PR-M03-19-NI-062
Accelerated Approval
Merck’s Keytruda to Get Accelerated FDA Evaluation for Treatment of Head and Neck Cancer
PAO-M02-19-NI-015
Biosimilars
U.S. Department of Veterans Affairs Signs Contract with Merck for its Remicade Biosimilar
PAO-M10-18-NI-010
FDA Approval
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
PR-M09-18-NI-070
FDA Approval
Merck’s HIV-1 Drugs Delstrigo and Pifeltro Get FDA Approval
PAO-M09-18-NI-003
Collaboration
Vyriad Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer
PR-M07-18-NI-065
Acquisition
P&G Acquires the Consumer Health Business of Merck KGaA, Darmstadt, Germany
PR-M04-18-NI-82
Oncology
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent
PR-M04-18-NI-63
Licensing
Merck Projected to Spend the Most on Licensing Deals in 2018
PAO-M04-18-NI-003
1
2
»
.svg)